Outcomes of Everolimus plus Exemestane in ER-positive, HER2-negative Heavily Pre-treated Metastatic Breast Cancer Patients: A Real Life Multicentre Experience

被引：0
|
作者：
Desai, P. [1 ]
Hogg, M. [2 ]
机构：
[1] Royal Preston Hosp, Preston, Lancs, England
[2] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
来源：
CLINICAL ONCOLOGY | 2018年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.clon.2018.02.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E42 / E43
页数：5
相关论文
共 50 条
  • [1] The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features
    Salaun, Helene
    Djerroudi, Lounes
    Haik, Laura
    Schnitzler, Anne
    Bataillon, Guillaume
    Deniziaut, Gabrielle
    Bieche, Ivan
    Vincent-Salomon, Anne
    Debled, Marc
    Cottu, Paul
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2024, 10 (03):
  • [2] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [3] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [4] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [5] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [6] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [7] The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
    Thibodeau, Stephane
    Voutsadakis, Ioannis A.
    EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (03) : 163 - 170
  • [8] Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
    Mery, Benoite
    Poulard, Coralie
    Le Romancer, Muriel
    Tredan, Olivier
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [9] Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Ghosh, J.
    Gulia, S.
    Gupta, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S292 - S292
  • [10] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
12345